ORLANDO, FL / ACCESSWIRE / March 12, 2019 / Leading cannabis testing lab and data firm Digipath Inc. (DIGP) made two compelling announcements in the last few days about the filing of provisional patents with the U.S. Patent and Trademark Office based around the Company's in-house discoveries related to terpenes. Terpenes, a name we suspect you will start hearing more and more often, are the major components of plant derived essential oils and have been used by humans for thousands of years (think aromatherapy). Terpenes are another category of chemicals made by most plants, including cannabis where they play the major factor in how THC or CBD affect a person withstandalone activity of their own. The terpene market is indeed a blooming subgroup of the overall cannabis revolution.
Let's take a look at the patents individually, and briefly:
Patent Announcement #1
"A METHOD FOR AUGMENTING TERPENE PROFILES IN BEER AND OTHER BEVERAGES."
The first patent announcement gives Digipath a potential presence in the emerging cannabis beverage market. Two factors suggest an increased cannabis presence in the industry. First, is the fact that beer and liquor sales are reportedly in decline following legalization of cannabis. As Digipath previously reported, a ten-year-long joint study confirmed a 13.8 percent drop in beer sales after marijuana legalization. Moreover, data confirms that sales of alcohol were, on average, fifteen percent lower in states with legalized cannabis. The same study also showed that marijuana and alcohol have a widely overlapping consumer base. ( Click here for the full story. ) It is reasonable to suggest that cannabis inspired alcohol products could be successful among this consumer base. In fact, if following the money means anything, beer mega-co Anheuser Busch announced a $100 million deal with Canadian cannabis giant Tilray to explore the weed/beer market.
Patent Announcement #2
''A METHOD OF DETERMINING TERPENE-BASED BIOCONTROL AGENTS FOR CANNABIS AND HEMP."
Obviously, a foray into the marriage of cannabis and beer is a sexy play in and of itself, the sort of thing that turns the head of the average retail investor. But Digipath's latest patent announcement, which reveals an industrial terpene application that is aimed to change the pesticide game on cannabis, is worthy of attention. Paramount is the fact that the technology confirms that Digipath has discovered a way to use plant-based terpenes to reduce failures for total yeast and mold and aerobic bacteria.
Digipath's own testing labs have affirmed a vast need for preventing the aforementioned in the cannabis samples they've tested, finding far too many samples that lead to expensive cannabis crop loss. But a side note in the release warrants mention, amplification even. The Company believes its terpenes technology is useful in other agricultural markets, not just cannabis.
All in all, Digipath is establishing itself as ''Cannabis-Tech,'' a cutting-edge confluence of inbound testing reliability and outbound technology monetization, and these patents, when awarded gives the Company lucrative Intellectual Property in a rapidly expanding marketplace always looking for innovation.
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
About SmallCap Sentinel:
SmallCap Sentinel is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid 50,000 dollars for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. A contributor to this report holds 400,000 shares and receives $3,500 a month for a period of six months for investor relations services on the behalf of Digipath.
Emerging Markets Consulting, LLC
15701 State Road 50, Suite #205
Clermont, FL 34711
SOURCE: Emerging Markets Report
View source version on accesswire.com: